The catecholamine release-inhibitory peptide catestatin (chromogranin A344-364)modulates myocardial function in fish

Journal of Experimental Biology

Volumn 213, Issue 21, 2010, Pages 3636-3643

  Imbrogno, Sandra ^a   Garofalo, Filippo ^a,b   Cerra, Maria Carmela ^b   Mahata, Sushil K ^c,d   Tota, Bruno ^a  

^a Department of Cell Biology ^*  (Australia)

^b UNIVERSITY OF CALABRIA   (Italy)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Anguilla Anguilla L.; Chromogranin A; Inotropic agents; Myocardial relaxation; Nitric oxide synthase; SERCA2a; Stroke volume

Indexed keywords

ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTOR; CHROMOGRANIN A; CHROMOGRANIN A (344 364); CHROMOGRANIN A (344-364); CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; NITRIC OXIDE; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BIOLOGICAL MODEL; BIOMECHANICS; CATTLE; CHEMISTRY; DRUG EFFECT; EEL; ENZYMOLOGY; HEART; HEART FUNCTION TEST; HEART MUSCLE; HEART STROKE VOLUME; HUMAN; IN VITRO STUDY; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION; PHYSIOLOGY; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANGUILLA; ANIMALS; BIOMECHANICS; BLOTTING, WESTERN; CATTLE; CHROMOGRANIN A; CYCLIC GMP; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HEART; HEART FUNCTION TESTS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECEPTORS, ADRENERGIC; RECEPTORS, CHOLINERGIC; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; STROKE VOLUME;

ANGUILLA ANGUILLA; ANURA; BOVINAE; MAMMALIA; RATTUS;

EID: 78149312248     PISSN: 00220949     EISSN: None     Source Type: Journal    
DOI: 10.1242/jeb.045567     Document Type: Article

References (47)

1. Aardal, S., Helle, K. B., Elsayed, S., Reed, R. K. and Serck-Hanssen, G. (1993). Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J. Neuroendocrinol. 5, 405-412.
2. Ai, T., Horie, M., Obayashi, K. and Sasayama, S. (1998). Accentuated antagonism by angiotensin II on guinea-pig cardiac L-type Ca-currents enhanced by b-adrenergic stimulation. Eur. J. Physiol. 436, 168-174.
3. Amelio, D., Garofalo, F., Pellegrino, D., Giordano, F., Tota, B. and Cerra, M. C. (2006). Cardiac expression and distribution of nitric oxide synthases in the ventricle of the cold-adapted Antarctic teleosts, the hemoglobinless Chionodraco hamatus and the red-blooded Trematomus bernacchii. Nitric Oxide 15, 190-198.
4. Angelone, T., Quintieri, A. M., Brar, B. K., Limchiyawat, P. T., Tota, B., Mahata, S. K. and Cerra, M. C. (2008). The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinol. 149, 4780-4793.
5. Cappello, S., Angelone, T., Tota, B., Pagliaro, P., Penna, C., Rastaldo, R., Corti, A., Losano, G. and Cerra, M. C. (2007). Human recombinant chromogranin Aderived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am. J. Physiol. Heart Circ. Physiol. 293, H719-H727.
6. Ceconi, C., Ferrari, R., Bachetti, T., Opasch, C., Volterrani, M., Colombo, B., Parinnello, G. and Corti, A. (2002). Chromogranin A in heart failure: a novel neurohumoral factor and a predictor for mortality. Eur. Heart J. 23, 967-974.
7. Cerra, M. C., De Iuri, L., Angelone, T., Corti, A. and Tota, B. (2006). Recombinant Nterminal fragments of chromogranin-A modulate cardiac function of the Langendorffperfused rat heart. Basic Res. Cardiol. 101, 43-52.
8. Cerra, M. C., Gallo, M. P., Angelone, T., Quintieri, A. M., Pulerà, E., Filice, E., Guérold, B., Shooshtarizadeh, P., Levi, R., Ramella, R. et al. (2008). The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endotheliumderived nitric oxide. FASEB J. 22, 3992-4004.
9. Corti, A., Mannarino, C., Mazza, R., Angelone, T., Longhi, R. and Tota, B. (2004). Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA7-57 peptide act as cardiostatins on the isolated working frog heart. Gen. Comp. Endocrinol. 136, 217-224.
10. Courel, M., Rodemer, C., Nguyen, S. T., Pance, A., Jackson, A. P., O'Connor, D. T. and Taupenot, L. (2006). Secretory granule biogenesis in sympathoadrenal cells: identification of a granulogenic determinant in the secretory prohormone chromogranin A. J. Biol. Chem. 281, 38038-38051.
11. Dondossola, E., Gasparri, A., Bachi, A., Longhi, R., Metz-Boutigue, M. H., Tota, B., Helle, K. B., Curnis, F. and Corti, A. (2010). Vasostatin-1 contains an ezrin-binding site that regulates cell adhesion. Cell. Mol. Life Sci. (In press).
12. Fabbri, E., Capuzzo, A. and Moon, T. W. (1998). The role of circulating catecholamines in the regulation of fish metabolism: an overview. Comp. Biochem. Physiol. C. Pharmacol. Toxicol. Endocrinol. 120, 177-192.
13. Farrell, A. P. and Jones, D. R. (1992). The heart. In Fish Physiology, Vol. 12A (ed. W. S. Hoar and D. J. Randall), pp. 1-88. London: Academic Press.
14. Fung, M. M., Salem, R. M., Mehtani, P., Thomas, B., Lu, C. F., Perez, B., Rao, F., Stridsberg, M., Ziegler, M., Mahata. S. K. and O'Connor, D. T. (2010). Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin. Exp. Hypertens. 32, 278-287.
15. Garofalo, F., Parisella, M. L., Amelio, D., Tota, B. and Imbrogno, S. (2009). Phospholamban S-nitrosylation modulates Starling response in fish heart. Proc. R. Soc. Lond. B. Biol. Sci. 276, 4043-4052.
16. Glattard, E., Angelone, T., Strub, J. M., Corti, A., Aunis, D., Tota, B., Metz-Boutigue, M. H. and Goumon, Y. (2006). Characterization of natural vasostatin-containing peptides in rat heart. FEBS J. 273, 3311-3321.
17. Helle, K. B., Corti, A., Metz-Boutigue, M.H. and Tota, B. (2007). The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell. Mol. Life Sci. 64, 2863-2886.
18. Imbrogno, S., De Iuri, L., Mazza, R. and Tota, B. (2001). Nitric Oxide modulates cardiac performance in the heart of Anguilla anguilla. J. Exp. Biol. 204, 1719-1727.
19. Imbrogno, S., Cerra, M. C. and Tota, B. (2003). Angiotensin II-induced inotropism requires an endocardial endothelium-nitric oxide mechanism in the in-vitro heart of Anguilla anguilla. J. Exp. Biol. 206, 2675-2684.
20. Imbrogno, S., Angelone, T., Corti, A., Adamo, C., Helle, K. B. and Tota, B. (2004). Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen. Comp. Endocrinol. 139, 20-28.
21. Imbrogno, S., Angelone, T., Adamo, C., Pulerà, E., Tota, B. and Cerra, M. C. (2006). Beta3-Adrenoreceptor in the eel (Anguilla anguilla) heart: negative inotropy and NOcGMP - Dependent mechanism. J. Exp. Biol. 209, 4966-4973.
22. Kennedy, B. P., Mahata, S. K., O'Connor, D. T. and Ziegler, M. G. (1998). Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 19, 1241-1248.
23. Koeslag, J. H., Saunders, P. T. and Wessels, J. A. (1999). The chromogranins and the counterregulatory hormones: do they make homeostatic sense? J. Physiol. 517, 643-649.
24. Krüger, P. G., Mahata, S. K. and Helle, K. B. (2003). Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul. Pept. 114, 29-35.
25. Mahapatra, N. R., O'Connor, D. T., Vaingankar, S. M., Hikim, A. P., Mahata, M., Ray, S., Staite, E., Wu, H., Gu, Y., Dalton, N. et al. (2005). Hypertension from targeted ablation of chromogranin A can be rescued in human ortholog. J. Clin. Invest. 115, 1942-1952.
26. Mahata, S. K., O'Connor, D. T., Mahata, M., Yoo, S. H., Taupenot, L., Wu, H., Gill, B. M. and Parmer, R. J. (1997). Novel autocrine feedback control of cathecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J. Clin. Invest. 100, 1623-1633.
27. Mahata, S. K., Mahata, M., Wakade, A. R. and O'Connor, D. T. (2000). Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): identification of amino acid residues crucial for activity. Mol. Endocrinol. 14, 1525-1535.
28. Mahata, S. K., Mahapatra, N. R., Mahata, M., Wang, T. C., Kennedy, B. P., Ziegler, M. G. and O'Connor, D. T. (2003). Catecholamine secretory vesicle stimulustranscription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J. Biol. Chem. 27, 32058-32067.
29. Mahata, S. K., Mahata, M., Wen, G., Wong, W. B., Mahapatra, N. R., Hamilton, B. A. and O'Connor, D. T. (2004). The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol. Pharmacol. 66, 1180-1191.
30. Mazza, R., Gattuso, A., Mannarino, C., Brar, B. K., Barbieri, S. F., Tota, B. and Mahata, S. K. (2008). Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am. J. Physiol. Heart Circ. Physiol. 295, H113-H122.
31. Muth, E., Driscoll, W. J., Smalstig, A., Goping, G. and Mueller, G. P. (2004). Proteomic analysis of rat atrial secretory granules: a platform for testable hypotheses. Biochim. Biophys. Acta 1699, 263-275.
32. O'Connor, D. T., Kailasam, M. T., Kennedy, B. P., Ziegler, M. G., Yanaihara, N. and Parmer, R. J. (2002). Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J. Hypertens. 20, 1335-1345.
33. Olson, R. K. (1998). The cardiovascular system. In The Physiology of Fishes (ed. H. D. Evans), pp. 129-154. Boca Raton, NY: CRC Press.
34. Pieroni, M., Bellocci, F., Sanna, T., Verardo, R., Ierardi, C., Maseri, A., Frustaci, A. and Crea, F. (2007). Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J. Card. Fail. 13, 380-388.
35. Schjolden, J., Stoskhus, A. and Winberg, S. (2005). Does individual variation in stress responses and agonistic behavior reflect divergent stress coping strategies in juvenile rainbow trout? Physiol. Biochem. Zool. 78, 715-723.
36. Seidah, N. G. and Chretien, M. (1999). Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 848, 45-62.
37. Steiner, H. J., Weiler, R., Ludescher, C., Schmid, K. W. and Winkler, H. (1990). Chromogranins A anb B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J. Histochem. Cytochem. 38, 845-850.
38. Strub, J. M., Goumon, Y., Lugardon, K., Capon, C., Lopez, M., Moniatte, M., Van Dorsselaer, A., Aunis, D. and Metz-Boutigue, M. H. (1996). Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules. J. Biol. Chem. 271, 28533-28540.
39. Takiyyuddin, M. A., Cervenka, J. H., Sullivan, P. A., Pandian, M. R., Parmer, R. J., Barbosa, J. A. and O'Connor, D. T. (1990). Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 81, 185-195.
40. Tatemoto, K., Efendic, S., Mutt, V., Makk, G., Feistner, G. J. and Barchas, J. D. (1986). Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324, 476-478.
41. Tota, B. and Gattuso, A. (1996). Heart ventricle pumps in teleosts and elasmobranches, a morphodynamic approach. J. Exp. Zool. 275, 162-171.
42. Tota, B., Mazza, R., Angelone, T., Nullans, G., Metz-Boutigue, M. H., Aunis, D. and Helle, K. B. (2003). Peptides from the N-terminal domain of Chromogranin A (Vasostatins) exert negative inotropic effects in the isolated frog heart. Regul. Pept. 114, 123-130.
43. Tota, B., Quintieri, A. M., Di Felice, V. and Cerra, M. C. (2007). New biological aspects of chromogranin A-derived peptides: focus on vasostatins. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 147, 11-18.
44. Van Raaij, M. T. M., Pit, D. S. S., Balm, P. H. M., Steffens, A. B. and van den Thillart, G. E. E. J. M. (1996). Behavioral strategy and the physiological stress response in rainbow trout exposed to severe hypoxia. Horm. Behav. 30, 85-92.
45. Vesely, D. L. (2006). Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? Clin. Exp. Pharmacol. Physiol. 33, 169-176.
46. Weiergraber, M., Pereverzev, A., Vajna, R., Henry, M., Schramm, M., Nastainczyk, W., Grabsch, H. and Schneider, T. (2000). Immunodetection of alpha1E voltagegated Ca(2+) channel in chromogranin-positive muscle cells of rat heart, and in distal tubules of human kidney. J. Histochem. Cytochem. 48, 807-819.
47. Winkler, H. and Fischer-Colbrie, R. (1992). The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49, 497-528.